← All organizations
Highest phase reached
Phase 2
Acquired by Amgen on Jan 1, 2012
Timeline
2000s
- Jan 1, 2003
KAI Pharmaceuticals— Founded
2010s
- Jan 1, 2012
Amgen— Acquired By
- Feb 7, 2017
etelcalcetide— NDA Secondary Org
Drugs by trial phase (6 distinct, 10 trials)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Bone Diseases
- Cardiovascular Diseases
- Chronic Kidney Disease-Mineral and Bone Disorder
- Hyperparathyroidism
- Hyperparathyroidism, Secondary
- Infarction
- Kidney Diseases
- Myocardial Infarction
- Neoplasm Metastasis
- Neuralgia
- Neuralgia, Postherpetic
- Pathologic Processes
- Postoperative Pain
- Renal Insufficiency, Chronic
- Spinal Cord Injuries
- Wounds and Injuries
Marketed drugs (1)
Recent trials (16)
- NCT01576146Lead sponsorPhase 2Mar 1, 2012
- NCT01414114Study directorPhase 2Dec 5, 2011
- NCT01414114Lead sponsorPhase 2Dec 5, 2011
- NCT01254565Lead sponsorPhase 2Feb 20, 2011
- NCT01134562Study directorPhase 1Aug 1, 2010
- NCT01134562Lead sponsorPhase 1Aug 1, 2010
- NCT01134549Lead sponsorPhase 1Jun 9, 2010
- NCT01106716Study directorPhase 2Mar 1, 2009
- NCT01106716Lead sponsorPhase 2Mar 1, 2009
- NCT01135108Lead sponsorPhase 2Mar 1, 2009
- NCT01135108Study directorPhase 2Mar 1, 2009
- NCT01015235Study directorPhase 2Dec 1, 2008
- NCT01015235Lead sponsorPhase 2Dec 1, 2008
- NCT00785954Lead sponsorPhase 2Nov 1, 2008
- NCT00785954Study directorPhase 2Nov 1, 2008
Details
- Founded
- South San Francisco, CA, US Jan 1, 2003
- Last known activity
- Mar 1, 2012